

# FGR Antibody (N-term)

Purified Rabbit Polyclonal Antibody (Pab) Catalog # AP7707A

# **Product Information**

Application	WB, IHC-P, IF, E
••	
Primary Accession	<u>P09769</u>
Reactivity	Human
Host	Rabbit
Clonality	Polyclonal
Isotype	Rabbit IgG
Calculated MW	59479
Antigen Region	3-33

# **Additional Information**

Gene ID	2268
Other Names	Tyrosine-protein kinase Fgr, Gardner-Rasheed feline sarcoma viral (v-fgr) oncogene homolog, Proto-oncogene c-Fgr, p55-Fgr, p58-Fgr, p58c-Fgr, FGR, SRC2
Target/Specificity	This FGR antibody is generated from rabbits immunized with a KLH conjugated synthetic peptide between 3-33 amino acids from the N-terminal region of human FGR.
Dilution	WB~~1:1000 IHC-P~~1:100~500 IF~~1:10~50 E~~Use at an assay dependent concentration.
Format	Purified polyclonal antibody supplied in PBS with 0.09% (W/V) sodium azide. This antibody is prepared by Saturated Ammonium Sulfate (SAS) precipitation followed by dialysis against PBS.
Storage	Maintain refrigerated at 2-8°C for up to 2 weeks. For long term storage store at -20°C in small aliquots to prevent freeze-thaw cycles.
Precautions	FGR Antibody (N-term) is for research use only and not for use in diagnostic or therapeutic procedures.

#### **Protein Information**

Name	FGR
Synonyms	SRC2
Function	Non-receptor tyrosine-protein kinase that transmits signals from cell

	surface receptors devoid of kinase activity and contributes to the regulation of immune responses, including neutrophil, monocyte, macrophage and mast cell functions, cytoskeleton remodeling in response to extracellular stimuli, phagocytosis, cell adhesion and migration. Promotes mast cell degranulation, release of inflammatory cytokines and IgE-mediated anaphylaxis. Acts downstream of receptors that bind the Fc region of immunoglobulins, such as MS4A2/FCER1B, FCGR2A and/or FCGR2B. Acts downstream of ITGB1 and ITGB2, and regulates actin cytoskeleton reorganization, cell spreading and adhesion. Depending on the context, activates or inhibits cellular responses. Functions as a negative regulator of ITGB2 signaling, phagocytosis and SYK activity in monocytes. Required for normal ITGB1 and ITGB2 signaling, normal cell spreading and adhesion in neutrophils and macrophages. Functions as a positive regulator of cell migration and regulates cytoskeleton reorganization via RAC1 activation. Phosphorylates SYK (in vitro) and promotes SYK-dependent activation of AKT1 and MAP kinase signaling. Phosphorylates PLD2 in antigen-stimulated mast cells, leading to PLD2 activation and the production of the signaling molecules lysophosphatidic acid and diacylglycerol. Promotes activation of PIK3R1. Phosphorylates FASLG, and thereby regulates its ubiquitination and subsequent internalization. Phosphorylates ABL1. Promotes phosphorylates HCLS1 that has already been phosphorylated by SYK, but not unphosphorylated HCLS1. Together with CLNK, it acts as a negative regulator of natural killer cell-activating receptors and inhibits interferon-gamma production (By similarity).
Cellular Location	Cell membrane; Lipid-anchor; Cytoplasmic side. Cell membrane; Peripheral membrane protein; Cytoplasmic side. Cell projection, ruffle membrane. Cytoplasm, cytosol. Cytoplasm, cytoskeleton. Mitochondrion inner membrane. Mitochondrion intermembrane space. Note=Detected in mitochondrial intermembrane space and at inner membranes (By similarity). Colocalizes with actin fibers at membrane ruffles. Detected at plasma membrane lipid rafts
Tissue Location	Detected in neutrophils, monocytes and natural killer cells (at protein level). Detected in monocytes and large lymphocytes.

## Background

FGR is a member of the Src family of protein tyrosine kinases (PTKs). This protein contains N-terminal sites for myristylation and palmitylation, a PTK domain, and SH2 and SH3 domains which are involved in mediating protein-protein interactions with phosphotyrosine-containing and proline-rich motifs, respectively. It localizes to plasma membrane ruffles, and functions as a negative regulator of cell migration and adhesion triggered by the beta-2 integrin signal transduction pathway. Infection with Epstein-Barr virus results in the overexpression of this protein.

## References

Carriero, M.V., et al., Biol. Chem. 383(1):107-113 (2002). Katamine, S., et al., Mol. Cell. Biol. 8(1):259-266 (1988). Nishizawa, M., et al., Mol. Cell. Biol. 6(2):511-517 (1986). Cheah, M.S., et al., Nature 319(6050):238-240 (1986). Tronick, S.R., et al., Proc. Natl. Acad. Sci. U.S.A. 82(19):6595-6599 (1985).

#### Images



whole cell lysate Lysates/proteins at 20 µg per lane. Secondary Goat Anti-Rabbit IgG, (H+L), Peroxidase conjugated at 1/10000 dilution. Predicted band size : 59 kDa Blocking/Dilution buffer: 5% NFDM/TBST.

Ant who Sec con 72 -55 -4 36 -28 -17 -

Anti-FGR Antibody (N-term) at 1:1000 dilution + Raji whole cell lysate Lysates/proteins at 20 µg per lane. Secondary Goat Anti-Rabbit IgG, (H+L), Peroxidase conjugated at 1/10000 dilution. Predicted band size : 59 kDa Blocking/Dilution buffer: 5% NFDM/TBST.

Western blot analysis of FGR (arrow) using FGR Antibody (N-term) (Cat.#AP7707a). 293 cell lysates (2 ug/lane) either nontransfected (Lane 1) or transiently transfected with the FGR gene (Lane 2) (Origene Technologies).



1 2

30 95 72

55

36

28

17

Formalin-fixed and paraffin-embedded human cancer tissue reacted with the primary antibody, which was peroxidase-conjugated to the secondary antibody, followed by AEC staining. This data demonstrates the use of this antibody for immunohistochemistry; clinical relevance has not been evaluated. BC = breast carcinoma; HC = hepatocarcinoma.

Confocal immunofluorescent analysis of FGR Antibody (N-term)(Cat#AP7707a) with MDA-MB231 cell followed by Alexa Fluor 488-conjugated goat anti-rabbit lgG (green).DAPI was used to stain the cell nuclear (blue).



# Citations

- High-throughput RNAi screening identifies a role for TNK1 in growth and survival of pancreatic cancer cells.
  SRC family kinase activity is up-regulated in hormone-refractory prostate cancer.

Please note: All products are 'FOR RESEARCH USE ONLY. NOT FOR USE IN DIAGNOSTIC OR THERAPEUTIC PROCEDURES'.